AbbVie
ABBV
3,332 hedge funds and large institutions have $193B invested in AbbVie in 2023 Q4 according to their latest regulatory filings, with 370 funds opening new positions, 1,176 increasing their positions, 1,425 reducing their positions, and 98 closing their positions.
278% more first-time investments, than exits
New positions opened: 370 | Existing positions closed: 98
85% more call options, than puts
Call options by funds: $4.51B | Put options by funds: $2.44B
51% more capital inflows, than outflows
Capital inflows: $7.98B | Capital outflows: $5.29B
7% more funds holding
Funds holding: 3,114 → 3,332 (+218)
0.82% more ownership
Funds ownership: 69.64% → 70.46% (+0.82%)
10% less funds holding in top 10
Funds holding in top 10: 224 → 202 (-22)
17% less repeat investments, than reductions
Existing positions increased: 1,176 | Existing positions reduced: 1,425
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$753M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$371M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$348M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$346M |
| 5 |
Morgan Stanley
New York
|
+$274M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$490M |
| 2 |
JP Morgan Chase
New York
|
-$468M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$379M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$244M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$205M |
ABBV Hedge Fund Activity: Q4 2023 in Review
3,332 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2023, worth a combined $193B — up 5.1% from $183B a quarter earlier.
Buyers outnumbered sellers: 370 funds opened new ABBV positions and 98 closed out — a net gain of 272 holders — while 1,176 added to existing stakes and 1,425 trimmed.
The largest buyer was BlackRock, adding an estimated $753M. The largest seller was T. Rowe Price Associates, cutting an estimated $490M.
- 3,332 institutional investors held AbbVie (ABBV) as of Q4 2023, up from 3,114 in Q3 2023.
- Funds reported $193B of AbbVie stock for Q4 2023, up 5.1% quarter-over-quarter.
- 370 funds opened new AbbVie positions in Q4 2023 and 98 closed out, a net change of +272 holders.
- The largest AbbVie buyer in Q4 2023 was BlackRock, an estimated $753M added.
- The largest AbbVie seller in Q4 2023 was T. Rowe Price Associates, an estimated $490M sold.
Based on aggregated 13F filings for Q4 2023.